Author:
Cuzzubbo S.,Javeri F.,Tissier M.,Roumi A.,Barlog C.,Doridam J.,Lebbe C.,Belin C.,Ursu R.,Carpentier A.F.
Reference95 articles.
1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010
2. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015
3. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013
4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015
5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
Cited by
387 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献